Loading...
XNYSRDY
Market cap12bUSD
Dec 20, Last price  
15.37USD
1D
1.65%
1Q
-80.43%
Jan 2017
-66.06%
Name

Dr Reddy's Laboratories Ltd

Chart & Performance

D1W1MN
XNYS:RDY chart
P/E
19.53
P/S
3.90
EPS
66.84
Div Yield, %
51.92%
Shrs. gr., 5y
0.06%
Rev. gr., 5y
12.66%
Revenues
279.16b
+13.54%
19,471,920,38424,329,784,29365,249,358,49950,005,640,00069,441,000,00070,277,000,00074,693,000,00096,737,000,000116,266,000,000132,170,000,000148,189,000,000154,708,000,000140,809,000,000142,028,000,000153,851,000,000174,600,000,000189,722,000,000214,391,000,000245,879,000,000279,164,000,000
Net income
55.68b
+23.56%
211,266,3641,633,054,1529,348,943,0964,678,040,000-5,168,000,0001,068,000,00011,040,000,00014,262,000,00016,777,000,00021,512,000,00022,179,000,00020,013,000,00012,039,000,0009,806,000,00018,795,000,00019,498,000,00017,238,000,00023,568,000,00045,067,000,00055,684,000,000
CFO
45.43b
-22.83%
2,291,615,6011,647,402,25011,832,504,5186,122,640,0004,505,000,00013,226,000,0008,009,000,00016,150,000,00013,317,000,00019,463,000,00025,033,000,00041,247,000,00021,513,000,00018,029,000,00028,704,000,00029,841,000,00035,703,000,00028,108,000,00058,873,000,00045,433,000,000
Dividend
Jul 30, 20240.47917 USD/sh
Earnings
Jan 28, 2025

Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
URL
https://www.drreddys.com/
IPO date
Jan 01, 1986
Employees
25,863
Domiciled in
IN
Incorporated in
IN

Valuation

Title
INR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
279,164,000
13.54%
245,879,000
14.69%
214,391,000
13.00%
Cost of revenue
138,430,000
168,219,000
118,033,000
Unusual Expense (Income)
NOPBT
140,734,000
77,660,000
96,358,000
NOPBT Margin
50.41%
31.58%
44.94%
Operating Taxes
16,186,000
15,412,000
8,730,000
Tax Rate
11.50%
19.85%
9.06%
NOPAT
124,548,000
62,248,000
87,628,000
Net income
55,684,000
23.56%
45,067,000
91.22%
23,568,000
36.72%
Dividends
(6,648,000)
(4,979,000)
(4,146,000)
Dividend yield
Proceeds from repurchase of equity
805,000
368,000
334,000
BB yield
Debt
Debt current
14,030,000
12,194,000
28,099,000
Long-term debt
9,487,000
2,556,000
8,709,000
Deferred revenue
1,555,000
1,597,000
Other long-term liabilities
4,939,000
2,991,000
882,000
Net debt
(63,208,000)
(58,087,000)
(15,543,000)
Cash flow
Cash from operating activities
45,433,000
58,873,000
28,108,000
CAPEX
(16,403,000)
(18,864,000)
(19,049,000)
Cash from investing activities
(40,283,000)
(41,371,000)
(26,387,000)
Cash from financing activities
(3,763,000)
(26,861,000)
(2,422,000)
FCF
86,383,000
63,876,000
72,322,000
Balance
Cash
81,470,000
66,748,000
44,365,000
Long term investments
5,255,000
6,089,000
7,986,000
Excess cash
72,766,800
60,543,050
41,631,450
Stockholders' equity
270,123,000
217,692,000
177,603,000
Invested Capital
232,742,200
186,039,950
179,777,550
ROIC
59.48%
34.03%
49.70%
ROCE
46.07%
31.40%
43.51%
EV
Common stock shares outstanding
166,708
166,382
166,339
Price
Market cap
EV
EBITDA
155,575,000
90,162,000
108,182,000
EV/EBITDA
Interest
1,711,000
1,428,000
958,000
Interest/NOPBT
1.22%
1.84%
0.99%